Larotrectinib Is Highly Active in Patients With Advanced Recurrent TRK Fusion Thyroid (TC) and Salivary Gland Cancers (SGC)
Year: 2018
Type: article
Authors: L. Wirth, A. Drilon, C. Albert, A. Farago, Wel-Diery, P. Ma, D. Sohal, L. Raez, C. Baik, M.S. Brose, R. Doebele, M. Cox, N. Ku, D. Hong
Institutions: Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Seattle Children's Hospital, Fox Chase Cancer Center, West Virginia University, Cleveland Clinic, Seattle Cancer Care Alliance, University of Washington, Abramson Cancer Center, University of Pennsylvania, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2790239606